MR/PET in neurology: Heiss looks at the development of simultaneous PET and MR clinical data acquisition and at current activities and future potential for synergetic real-time recording of functional, metabolic, physiologic, and morphologic data.
Page 993
Immuno-PET of EGFRs: Kramer-Marek and Oyen describe the status of human epidermal growth factor receptor–specific imaging agents and efforts to move these molecular probes from early preclinical studies to clinical trials.
Page 996
177Lu-PSMA in prostate cancer: Kwekkeboom offers perspective on the use of 177Lu-labeled prostate-specific membrane antigen ligands in therapy targeting castration-resistant prostate cancer cells and previews a related article in this issue of JNM.
Page 1002
Chemokine receptor imaging: Bengel provides insight into research targeting visualization and quantification of the chemokine–chemokine receptor axis, with a focus on potential roles in exploring inflammatory processes.
Page 1004
177Lu-PSMA assessment: Baum and colleagues report on the safety and efficacy of a 177Lu-labeled DOTAGA-based prostate-specific membrane antigen ligand in patients with metastatic castration-resistant prostate cancer.
Page 1006
Dose–response in 90Y radioembolization: van den Hoven and colleagues characterize the relationship between tumor-absorbed dose and response after 90Y-microsphere radioembolization in patients with colorectal liver metastases.
Page 1014
Sphere numbers in radioembolization: Pasciak and colleagues investigate microscopic absorbed-dose heterogeneity in 90Y radioembolization as a function of microsphere numbers per unit volume in tumors and discuss potential related effects on tumor control and treatment planning.
Page 1020
Dose–response in DTC with 124I: Wierts and colleagues use a fixed-activity approach in 124I PET/CT quantification of the dose–response relationship in 124I-sodium iodide treatment of differentiated thyroid cancer.
Page 1027
NSCLC tumor heterogeneity: Tixier and colleagues quantify differences between volumetry, uptake, and heterogeneity features extracted from static and parametric PET images of non–small cell lung carcinoma and describe the potential added value of parametric images.
Page 1033
18F-FDG uptake and HER2 expression: Chen and colleagues investigate an association between human epidermal growth factor receptor 2 expression and tracer uptake and the potential for 18F-FDG PET/CT prediction of HER2 status in gastric cancer.
Page 1040
Posttransplantation volumetric PET in HCC: Kim and colleagues compare recently introduced metabolic and volumetric 18F-FDG PET/CT indices with current clinicopathologic data as predictors of hepatocellular carcinoma recurrence after liver transplantation.
Page 1045
PET/CT and liver metastasis ablation: Cornelis and colleagues determine whether 18F-FDG PET/CT and contrast-enhanced CT performed immediately after percutaneous ablation of liver metastases are predictors of local treatment failure at 1 year.
Page 1052
18F-choline PET/CT in CRPC: Lee and colleagues explore the serial application of metabolically active tumor volume measurements from 18F-fluorocholine PET/CT as systemic treatment response markers and predictors of disease progression in patients with castration-resistant prostate cancer.
Page 1058
18F-choline PET/MR for prostate biopsy: Piert and colleagues compare the value of fusion 18F-fluoromethylcholine PET/MR imaging for targeted prostate biopsies with that of standard systematic 12-core biopsies to detect significant prostate cancer.
Page 1065
11C-DED and 11C-PiB in brain perfusion: Rodriguez-Vieitez and colleagues compare early-phase 11C-DED and 11C-Pittsburgh compound B PET imaging as surrogate markers of brain perfusion in cognitive decline and determine the extent to which brain perfusion influences 11C-DED binding.
Page 1071
Variable-depth 3D-SSP for amyloid PET: Lilja and colleagues report on a method for 3-dimensional stereotactic surface projection quantification and visualization of 18F-flutemetamol images that avoids extraction of white matter signal.
Page 1078
Motion correction for dynamic PET: Yu and colleagues apply an event-by-event respiratory motion–correction method, correlating internal organ motion and external respiratory signals, to human dynamic PET studies and investigate the impact on kinetic parameter estimation.
Page 1084
ASiR and bone SPECT/CT: Sibille and colleagues compare a routine bone SPECT/CT protocol using CT reconstructed with filtered backprojection with an optimized protocol using low-dose CT images reconstructed with adaptive statistical iterative reconstruction.
Page 1091
MR-AC reproducibility and LBM extraction: Rausch and colleagues assess the reproducibility of standard Dixon-based attenuation correction in PET/MR imaging and use resulting data to estimate patient-specific lean body mass.
Page 1096
Lesion number, PERCIST, and breast cancer: Pinker and colleagues explore the question of whether and how the number of analyzed lesions affects standardized response assessment in metastatic breast cancer.
Page 1102
Immuno-PET and RIT in ESCC: Song and colleagues study the abilities of 64Cu-cetuximab immuno-PET to image epidermal growth factor receptor expression levels in esophageal squamous cell carcinoma tumors and of 177Lu-cetuximab radioimmunotherapy to inhibit tumor growth in mouse models.
Page 1105
Tissue factor imaging in pancreatic cancer: Nielsen and colleagues investigate the possibility of using active site–inhibited factor VII labeled with 64Cu for PET imaging of tissue factor expression in mice with pancreatic adenocarcinomas.
Page 1112
Biodistribution of NTR1 antagonists: Schulz and colleagues evaluate the biodistribution profiles of a series of newly developed diarylpyrazole-based neurotensin receptor–1 antagonists for suitability as diagnostic and radiotherapeutic agents.
Page 1120
Nanoparticle imaging of atherosclerosis: Luehmann and colleagues describe a targeted nanoparticle for sensitive and specific detection of chemokine receptors regulating trafficking of inflammatory cells in a mouse vascular injury model and in a mouse atherosclerosis model.
Page 1124
High-resolution mouse brain PET scanner: Yang and colleagues detail the development of a prototype small-animal PET scanner based on depth-encoding detectors using dual-ended readout of small scintillator elements to produce high and uniform spatial resolution.
Page 1130
Single-cell 18F-FLT characterization: Sengupta and Pratx use a novel in vitro radioluminescence microscopy technique to measure the differential distribution of 18F-FLT radiotracer with single-cell precision.
Page 1136
PET mapping for brain–computer interface: Zhu and colleagues investigate the use of PET mapping for brain–computer interface stimulation in a rat model with electrodes implanted in the ventroposterior medial thalamus.
Page 1141
Nuclear medicine physics training: Harkness and Fahey summarize the findings of an American Association of Physicists in Medicine/SNMMI joint task force reviewing nuclear medicine physics training and identifying ways to improve future training opportunities.
Page 1146
Administered activities in pediatrics: Fahey and colleagues present part 2 of the final report of the Nuclear Medicine Global Initiative, surveying standards and practice for administered activities in children and offering recommendations toward global standardization of radiopharmaceutical administration.
Page 1148
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.